Climb Bio, Inc. Engages Investors at Major Healthcare Events
Climb Bio, Inc. (NASDAQ: CLYM) is making waves in the biotechnology sector with its commitment to developing innovative therapies for immune-mediated diseases. The company recently announced its participation in a series of investor conferences that will spotlight its progress and future potential.
Participating in Key Investor Conferences
The executive team from Climb Bio is set to participate in three significant conferences. This is an exciting opportunity for investors to gain insights into the company's strategic direction, therapeutic developments, and engage directly with management.
Guggenheim Healthcare Innovation Conference
One of the notable events is the Guggenheim's 2nd Annual Healthcare Innovation Conference. This conference will take place in Boston, featuring a fireside chat format that allows for interactive discussions and one-on-one investor meetings on November 10, 2025, at 11:30 a.m. ET.
Baird Biotech Discovery Series
Another key event is the Baird Biotech Discovery Series, which is a virtual conference. Slated for November 18, 2025, at 1:30 p.m. ET, this conference will also feature a fireside chat, allowing attendees to explore Climb Bio's innovative pipeline.
Piper Sandler's Annual Healthcare Conference
Finally, Climb Bio will also showcase its advancements at Piper Sandler's 37th Annual Healthcare Conference in New York on December 2, 2025, at 9:30 a.m. ET. This event will also follow a fireside chat format combined with one-on-one meetings.
Accessing the Live Webcasts
Investors who are interested in following Climb Bio's presentations can access live webcasts through the 'Investors & Media' section of the Climb Bio website. These webcasts will provide valuable information about the company's innovations and developments in the pipeline.
About Climb Bio, Inc.
Climb Bio, Inc. is at the forefront of biotechnology, focusing on therapeutics that target immune-mediated diseases. The company is advancing a robust pipeline that includes budoprutug, an anti-CD19 monoclonal antibody aimed at treating various B-cell mediated diseases, as well as CLYM116, an anti-APRIL monoclonal antibody intended for IgA nephropathy.
Contact Information
For press and investor inquiries, Carlo Tanzi, Ph.D., from Kendall Investor Relations is the contact person. He can be reached at ctanzi@kendallir.com for any additional information regarding the company's innovations or conference details.
Frequently Asked Questions
What is Climb Bio, Inc. focusing on?
Climb Bio, Inc. is dedicated to developing therapeutics for immune-mediated diseases through innovative biotechnology approaches.
When will the investor conferences take place?
The conferences will occur on November 10, November 18, and December 2, 2025.
Where can I watch Climb Bio's presentations?
Live webcasts will be available on the Climb Bio website under the 'Investors & Media' section.
Who is the contact for investor relations?
Carlo Tanzi, Ph.D., is the contact for investor inquiries and can be reached via email for any questions.
What products is Climb Bio developing?
Climb Bio is developing budoprutug for B-cell mediated diseases and CLYM116 for IgA nephropathy.